Cargando…
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049565/ https://www.ncbi.nlm.nih.gov/pubmed/21224852 http://dx.doi.org/10.1038/sj.bjc.6606068 |
| _version_ | 1782199239759101952 |
|---|---|
| author | Garantziotis, S |
| author_facet | Garantziotis, S |
| author_sort | Garantziotis, S |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-3049565 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2011 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-30495652012-02-01 Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value Garantziotis, S Br J Cancer Letter to the Editor Nature Publishing Group 2011-02-01 2011-01-11 /pmc/articles/PMC3049565/ /pubmed/21224852 http://dx.doi.org/10.1038/sj.bjc.6606068 Text en Copyright © 2011 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter to the Editor Garantziotis, S Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value |
| title | Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value |
| title_full | Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value |
| title_fullStr | Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value |
| title_full_unstemmed | Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value |
| title_short | Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value |
| title_sort | modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049565/ https://www.ncbi.nlm.nih.gov/pubmed/21224852 http://dx.doi.org/10.1038/sj.bjc.6606068 |
| work_keys_str_mv | AT garantziotiss modulationofplasmacomplementbytheinitialdoseofepirubicindocetaxeltherapyinbreastcanceranditspredictivevalue |